4 articles
Gilead Sciences agreed to acquire PepStar Therapeutics' oral inflammation drug program for $1.275 billion in cash. The deal adds HCXT-2001, an experimental treatment targeting the IL-23 pathway for in
Gilead Sciences completed a $3.15 billion acquisition of Tubulis, an academic start-up co-founded by Prof. Christian Hackenberger, to commercialize its antibody-drug conjugate technology.
The California Supreme Court will hear arguments on whether drugmakers face a legal 'duty to innovate,' specifically in a Gilead Sciences case involving HIV medication development delays. A ruling cou
Gilead Sciences' HIV prevention injection Yeztugo sees rising usage since launch, though insurance coverage gaps and high costs hinder widespread adoption compared to daily pills. Analysts project ann
ChemBrief